Today: 20 May 2026
Browse Category

LSE:GSK 30 July 2025 - 8 December 2025

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK shares traded near multi-year highs on 4 December, closing at 1,826–1,837p in London and $48.57 in New York, up over 40% year-to-date. The company repurchased more than 11.5 million shares since late September as part of a £2 billion buyback. New executive share options were granted on 5 December. Market cap stands at about £73 billion in London and just under $100 billion in New York.
5 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK closed near 1,783p in London on 2 December 2025, just below its 52-week high, after strong Q2 and Q3 results lifted shares nearly 40% over 12 months. Q3 sales rose 8% at constant exchange to £8.5 billion, with oncology up 39% and core EPS up 14%. The ADR ended at $47.19 in New York. Analyst focus remains on the company’s growth pipeline and 2031 revenue targets.
2 December 2025
····
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

GSK shares closed up 0.23% at 1,776p in London on Thursday, trading between 1,772p and 1,790p on light volume. Jefferies raised its target price to 2,100p and reiterated a “Buy” rating. Recent R&D announcements and a new oncology collaboration with LTZ Therapeutics continued to influence sentiment. Over the past year, GSK shares have gained about 36%.
20 November 2025
··
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

The Stoxx 600 rose 0.18% to 555.53 on Sept. 29, with Germany’s DAX and the FTSE 100 also edging higher, while Italy’s FTSE MIB and Spain’s IBEX 35 slipped 0.22%. Euro-area economic confidence beat forecasts, and German import prices fell 1.5% year-on-year. Healthcare, luxury, and mining stocks gained; banks and energy lagged. GSK jumped on CEO news, while Carnival dropped 4.5% despite raising profit forecasts.
30 September 2025
······
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European stocks closed higher Monday, with the FTSE 100 up 0.5% and the STOXX 600 gaining 0.2% as healthcare and tech outperformed. GSK surged 3.3% after CEO Emma Walmsley’s exit was announced; AstraZeneca rose 1.3% on plans for a New York listing. Lufthansa said it will cut 4,000 jobs. Oil fell 0.6% on resumed Iraqi Kurdish exports and OPEC+ supply news; gold hit a record $3,812 an ounce.
29 September 2025
·······
Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus

Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus

S&P 500 futures rose 0.3% Monday as Congress faced a Tuesday midnight deadline to avert a U.S. government shutdown. Gold hit a record $3,808/oz, while oil slipped near $70 on OPEC+ news. AstraZeneca shares gained 1.3% on its NYSE listing plan; First Brands Group filed for Chapter 11. Investors trimmed Fed rate-cut bets amid mixed economic data and looming jobs report.
29 September 2025
·······
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging

Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging

Altos Labs, a $3 billion biotech startup backed by Jeff Bezos, published a 2024 study showing partial cellular reprogramming extended lifespan and improved health in mice. The company, led by Hal Barron and Nobel laureate Shinya Yamanaka, focuses on rejuvenating cells to extend healthy years, not immortality. Altos faces competition from firms like Calico and Retro Biosciences in the fast-growing longevity sector.
20 September 2025
··
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

The FDA approved Leqembi IQLIK, the first at-home injectable Alzheimer’s treatment, enabling weekly self-administered doses. U.S. regulators also cleared Sanofi’s Wayrilz, the first BTK inhibitor for chronic immune thrombocytopenia. Cytokinetics’ aficamten outperformed metoprolol in a Phase 3 heart drug trial. WHO warned Gaza has run out of critical medical supplies amid a spike in Guillain-Barré syndrome cases.
30 August 2025
····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis said two Phase III trials of ianalumab met primary endpoints in Sjögren’s disease, showing significant disease activity reduction. Boehringer Ingelheim’s zongertinib won accelerated FDA approval for HER2-mutant NSCLC. GSK’s gepotidacin received FDA Priority Review for uncomplicated gonorrhea. The U.S. Postal Service began blocking shipments of illicit vaping products amid regulatory scrutiny.
11 August 2025
····
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung unveiled the Galaxy Z Fold7 at $1,999 and the Flip7 FE at $899, with the Fold7 26% thinner and 10% lighter than last year’s model. Opera filed an antitrust complaint in Brazil against Microsoft over Edge’s default status. Sony sued Tencent, alleging Light of Motiram copied Horizon Zero Dawn. Figma raised its IPO price range, targeting an $18.8 billion valuation.
30 July 2025
·············
1 2 3 4

Stock Market Today

  • Stocks Added to Zacks Strong Sell List on May 20th: BRCC, CVE, MITT
    May 20, 2026, 5:27 AM EDT. Three stocks joined the Zacks Rank #5 (Strong Sell) list on May 20th. BRC Inc. (BRCC), a coffee and apparel seller, saw its current year earnings estimate cut by 33.3%. Cenovus Energy Inc. (CVE), an oil and gas producer, had its earnings forecast lowered by 24.5%. AG Mortgage Investment Trust (MITT), a residential mortgage REIT, faced a 17.5% earnings revision downward. These revisions reflect growing bearish sentiment as analysts adjust expectations. The Zacks Rank #5 indicates a strong sell recommendation based on recent downward earnings revisions over 60 days.

Latest articles

Intel’s AI Comeback Just Got a $150 Wall Street Test

Intel’s AI Comeback Just Got a $150 Wall Street Test

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
Marvell shares active as earnings approach, AI chip focus in view

Marvell shares active as earnings approach, AI chip focus in view

20 May 2026
Marvell Technology shares rose 4.53% to $184.25 in premarket trading Wednesday, extending Tuesday’s 4.35% gain. The company will report fiscal Q1 2027 results after the close on May 27. Analysts at Evercore ISI, Melius Research, and CLSA raised price targets, citing strong demand for custom AI chips. Marvell posted record fiscal 2026 revenue of $8.195 billion in March.
SpaceX restarts Starlink launches after satellite mishap — and another Falcon 9 is already queued

SpaceX IPO Moves Closer as Goldman Nears Top Role in $1.75 Trillion Listing

20 May 2026
Goldman Sachs is set to lead SpaceX’s planned IPO, which could become the largest in history, with a targeted valuation of about $1.75 trillion, Reuters reported. SpaceX aims to publish its prospectus as soon as Wednesday and list on Nasdaq under the ticker SPCX as early as June 12. The company’s next Starship test flight is scheduled for May 21 from Texas. Morgan Stanley, Bank of America, Citigroup, and JPMorgan are also expected to play major roles.
Go toTop